
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7111330/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Glioma Groups Based on 1p/19q, <i>IDH</i> , and <i>TERT</i> Promoter Mutations in Tumors. New England Journal of Medicine, 2015, 372, 2499-2508.	13.9	1,632
2	Prediction error estimation: a comparison of resampling methods. Bioinformatics, 2005, 21, 3301-3307.	1.8	1,045
3	Genetic and molecular epidemiology of adult diffuse glioma. Nature Reviews Neurology, 2019, 15, 405-417.	4.9	437
4	Survival and low-grade glioma: the emergence of genetic information. Neurosurgical Focus, 2015, 38, E6.	1.0	358
5	Awake craniotomy to maximize glioma resection: methods and technical nuances over a 27-year period. Journal of Neurosurgery, 2015, 123, 325-339.	0.9	334
6	Association of Maximal Extent of Resection of Contrast-Enhanced and Non–Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma. JAMA Oncology, 2020, 6, 495.	3.4	325
7	Biomarker Expression and Risk of Subsequent Tumors After Initial Ductal Carcinoma In Situ Diagnosis. Journal of the National Cancer Institute, 2010, 102, 627-637.	3.0	304
8	Adverse radiation effect after stereotactic radiosurgery for brain metastases: incidence, time course, and risk factors. Journal of Neurosurgery, 2015, 123, 373-386.	0.9	247
9	Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathologica, 2017, 133, 1001-1016.	3.9	245
10	DNA Methylation and Somatic Mutations Converge on the Cell Cycle and Define Similar Evolutionary Histories in Brain Tumors. Cancer Cell, 2015, 28, 307-317.	7.7	221
11	Toward precision medicine in glioblastoma: the promise and the challenges. Neuro-Oncology, 2015, 17, 1051-1063.	0.6	178
12	Variants near TERT and TERC influencing telomere length are associated with high-grade glioma risk. Nature Genetics, 2014, 46, 731-735.	9.4	161
13	<i>CDKN2A</i> Loss Is Associated With Shortened Overall Survival in Lower-Grade (World Health) Tj ETQq1 1 0.7 2015, 74, 442-452.	784314 rgł 0.9	3T /Overlock 144
14	Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant <i>IDH1</i> . Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10743-10748.	3.3	109
15	Enhanced cell deconvolution of peripheral blood using DNA methylation for high-resolution immune profiling. Nature Communications, 2022, 13, 761.	5.8	93
16	Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma. Journal of Neuro-Oncology, 2016, 130, 543-552.	1.4	90
17	Longer genotypically-estimated leukocyte telomere length is associated with increased adult glioma risk. Oncotarget, 2015, 6, 42468-42477.	0.8	87
18	Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma. Journal of Neuro-Oncology, 2018, 140, 477-483.	1.4	82

#	Article	IF	CITATIONS
19	Telomere maintenance and the etiology of adult glioma. Neuro-Oncology, 2015, 17, 1445-1452.	0.6	70
20	Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma. Journal of Clinical Investigation, 2020, 130, 6325-6337.	3.9	70
21	Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma. Clinical Cancer Research, 2018, 24, 295-305.	3.2	68
22	Surgical assessment of the insula. Part 2: validation of the Berger-Sanai zone classification system for predicting extent of glioma resection. Journal of Neurosurgery, 2016, 124, 482-488.	0.9	65
23	Metabolic Profiling of IDH Mutation and Malignant Progression in Infiltrating Glioma. Scientific Reports, 2017, 7, 44792.	1.6	63
24	Understanding inherited genetic risk of adult glioma – a review. Neuro-Oncology Practice, 2016, 3, 10-16.	1.0	62
25	Effect of Provider Experience on Clinician-Performed Ultrasonography for Hydronephrosis in Patients With Suspected Renal Colic. Annals of Emergency Medicine, 2014, 64, 269-276.	0.3	60
26	Immunomethylomic approach to explore the blood neutrophil lymphocyte ratio (NLR) in glioma survival. Clinical Epigenetics, 2017, 9, 10.	1.8	60
27	Quantitative assessment shows loss of antigenic epitopes as a function of pre-analytic variables. Laboratory Investigation, 2011, 91, 1253-1261.	1.7	55
28	MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence. Neuro-Oncology, 2020, 22, 1580-1590.	0.6	55
29	Tree-based multivariate regression and density estimation with right-censored data. Journal of Multivariate Analysis, 2004, 90, 154-177.	0.5	52
30	Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade <i>IDH</i> -mutant gliomas. Neuro-Oncology, 2021, 23, 1872-1884.	0.6	48
31	The Effect of Timing of Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma. Neurosurgery, 2015, 77, 248-253.	0.6	47
32	Phase I study of vemurafenib in children with recurrent or progressive BRAFV600E mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002). Oncotarget, 2020, 11, 1942-1952.	0.8	45
33	Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma. Neuro-Oncology, 2014, 16, 1255-1262.	0.6	44
34	Probing the phosphatidylinositol 3â€kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult lowâ€grade gliomas. Cancer, 2017, 123, 4631-4639.	2.0	43
35	An independently validated nomogram for isocitrate dehydrogenase-wild-type glioblastoma patient survival. Neuro-Oncology Advances, 2019, 1, vdz007.	0.4	40
36	GBM heterogeneity as a function of variable epidermal growth factor receptor variant III activity. Oncotarget, 2016, 7, 79101-79116.	0.8	39

ANNETTE M MOLINARO

#	Article	IF	CITATIONS
37	Temporal Dynamics of Pseudoprogression After Gamma Knife Radiosurgery for Vestibular Schwannomas—A Retrospective Volumetric Study. Neurosurgery, 2019, 84, 123-131.	0.6	39
38	<i>partDSA</i> : deletion/substitution/addition algorithm for partitioning the covariate space in prediction. Bioinformatics, 2010, 26, 1357-1363.	1.8	37
39	Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adults. Neuro-Oncology Advances, 2020, 2, vdaa142.	0.4	35
40	Presence of cerebral microbleeds is associated with worse executive function in pediatric brain tumor survivors. Neuro-Oncology, 2016, 18, now163.	0.6	33
41	The effects of anti-angiogenic therapy on the formation of radiation-induced microbleeds in normal brain tissue of patients with glioma. Neuro-Oncology, 2016, 18, 87-95.	0.6	33
42	Indications and Efficacy of Gamma Knife Stereotactic Radiosurgery for Recurrent Glioblastoma: 2 Decades of Institutional Experience. Neurosurgery, 2017, 80, 129-139.	0.6	33
43	A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma. Cancer Chemotherapy and Pharmacology, 2017, 79, 603-610.	1.1	32
44	Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas. Journal of Clinical Investigation, 2022, 132, .	3.9	32
45	Diagnostic tests: how to estimate the positive predictive value. Neuro-Oncology Practice, 2015, 2, 162-166.	1.0	30
46	Improved Survival with Decreased Wait Time to Surgery in Glioblastoma Patients Presenting with Seizure. Neurosurgery, 2017, 81, 824-833.	0.6	30
47	Postoperative Delirium in Glioblastoma Patients: Risk Factors and Prognostic Implications. Neurosurgery, 2018, 83, 1161-1172.	0.6	29
48	Magnetic resonance analysis of malignant transformation in recurrent glioma. Neuro-Oncology, 2016, 18, 1169-1179.	0.6	28
49	Detection of glioma infiltration at the tumor margin using quantitative stimulated Raman scattering histology. Scientific Reports, 2021, 11, 12162.	1.6	28
50	PKM2 uses control of HuR localization to regulate p27 and cell cycle progression in human glioblastoma cells. International Journal of Cancer, 2016, 139, 99-111.	2.3	25
51	Risk factors of radiotherapyâ€induced cerebral microbleeds and serial analysis of their size compared with white matter changes: A 7T MRI study in 113 adult patients with brain tumors. Journal of Magnetic Resonance Imaging, 2019, 50, 868-877.	1.9	25
52	Doubly robust survival trees. Statistics in Medicine, 2016, 35, 3595-3612.	0.8	24
53	Using germline variants to estimate glioma and subtype risks. Neuro-Oncology, 2019, 21, 451-461.	0.6	23
54	Residual Tumor Volume and Location Predict Progression After Primary Subtotal Resection of Sporadic Vestibular Schwannomas: A Retrospective Volumetric Study. Neurosurgery, 2020, 86, 410-416.	0.6	22

#	Article	IF	CITATIONS
55	Developing an Algorithm for Optimizing Care of Elderly Patients With Glioblastoma. Neurosurgery, 2018, 82, 64-75.	0.6	22
56	Improving the noninvasive classification of glioma genetic subtype with deep learning and diffusion-weighted imaging. Neuro-Oncology, 2022, 24, 639-652.	0.6	22
57	Power of Data Mining Methods to Detect Genetic Associations and Interactions. Human Heredity, 2011, 72, 85-97.	0.4	21
58	A Partitioning Deletion/Substitution/Addition Algorithm for Creating Survival Risk Groups. Biometrics, 2012, 68, 1146-1156.	0.8	21
59	The Genetics of Splicing in Neuroblastoma. Cancer Discovery, 2015, 5, 380-395.	7.7	20
60	Statistical considerations on prognostic models for glioma. Neuro-Oncology, 2016, 18, 609-623.	0.6	20
61	Adult diffuse glioma GWAS by molecular subtype identifies variants in <i>D2HGDH</i> and <i>FAM20C</i> . Neuro-Oncology, 2020, 22, 1602-1613.	0.6	19
62	Association of Neurological Impairment on the Relative Benefit of Maximal Extent of Resection in Chemoradiation-Treated Newly Diagnosed Isocitrate Dehydrogenase Wild-Type Glioblastoma. Neurosurgery, 2022, 90, 124-130.	0.6	17
63	Reirradiation of recurrent high-grade glioma and development of prognostic scores for progression and survival. Neuro-Oncology Practice, 2019, 6, 364-374.	1.0	16
64	The impact of obesity on perioperative complications in patients undergoing anterior lumbar interbody fusion. Journal of Neurosurgery: Spine, 2020, 33, 332-341.	0.9	16
65	Risk prediction for local versus regional/metastatic tumors after initial ductal carcinoma in situ diagnosis treated by lumpectomy. Breast Cancer Research and Treatment, 2016, 157, 351-361.	1.1	15
66	Characterization of Metabolic, Diffusion, and Perfusion Properties in GBM: Contrast-Enhancing versus Non-Enhancing Tumor. Translational Oncology, 2017, 10, 895-903.	1.7	15
67	The influence of race and socioeconomic status on therapeutic clinical trial screening and enrollment. Journal of Neuro-Oncology, 2020, 148, 131-139.	1.4	15
68	PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications. Neuro-Oncology, 2022, 24, 1471-1481.	0.6	14
69	Phase I trial of caudate deep brain stimulation for treatment-resistant tinnitus. Journal of Neurosurgery, 2020, 133, 992-1001.	0.9	13
70	Immune profiles and DNA methylation alterations related with non-muscle-invasive bladder cancer outcomes. Clinical Epigenetics, 2022, 14, 14.	1.8	13
71	Longer genotypically-estimated leukocyte telomere length is associated with increased meningioma risk. Journal of Neuro-Oncology, 2019, 142, 479-487.	1.4	11
72	Rate of radiation-induced microbleed formation on 7T MRI relates to cognitive impairment in young patients treated with radiation therapy for a brain tumor. Radiotherapy and Oncology, 2021, 154, 145-153.	0.3	11

5

#	Article	IF	CITATIONS
73	Interactions of Age and Blood Immune Factors and Noninvasive Prediction of Glioma Survival. Journal of the National Cancer Institute, 2022, 114, 446-457.	3.0	11
74	Comparative Sensitivity of Intraoperative Motor Evoked Potential Monitoring in Predicting Postoperative Neurologic Deficits: Nondegenerative versus Degenerative Myelopathy. Global Spine Journal, 2016, 6, 452-458.	1.2	10
75	Identifying Voxels at Risk for Progression in Glioblastoma Based on Dosimetry, Physiologic and Metabolic MRI. Radiation Research, 2017, 188, 303.	0.7	10
76	Smoking Is an Independent Risk Factor for 90-Day Readmission and Reoperation Following Posterior Cervical Decompression and Fusion. Neurosurgery, 2021, 88, 1088-1094.	0.6	10
77	Prospective genomically guided identification of "early/evolving―and "undersampled―IDH-wildtype glioblastoma leads to improved clinical outcomes. Neuro-Oncology, 2022, 24, 1749-1762.	0.6	10
78	Relationship of In Vivo MR Parameters to Histopathological and Molecular Characteristics of Newly Diagnosed, Nonenhancing Lower-Grade Gliomas. Translational Oncology, 2018, 11, 941-949.	1.7	8
79	Clinical trial endpoints for patients with gliomas. Neuro-Oncology Practice, 2017, 4, 201-208.	1.0	7
80	The immunogenetics of viral antigen response is associated with subtype-specific glioma risk and survival. American Journal of Human Genetics, 2022, 109, 1105-1116.	2.6	7
81	Pre-surgery immune profiles of adult glioma patients. Journal of Neuro-Oncology, 2022, 159, 103-115.	1.4	7
82	A single institution retrospective analysis on survival based on treatment paradigms for patients with anaplastic oligodendroglioma. Journal of Neuro-Oncology, 2021, 153, 447-454.	1.4	6
83	Reducing complication rates for repeat craniotomies in glioma patients: a single-surgeon experience and comparison with the literature. Acta Neurochirurgica, 2022, 164, 405-417.	0.9	6
84	Skin disease in goats (<i>Capra aegagrus hircus</i>): a retrospective study of 358 cases at a university veterinary teaching hospital (1988–2020). Veterinary Dermatology, 2022, 33, 227.	0.4	6
85	Recurrent tumor and treatment-induced effects have different MR signatures in contrast enhancing and non-enhancing lesions of high-grade gliomas. Neuro-Oncology, 2020, 22, 1516-1526.	0.6	5
86	Germline polymorphisms in myeloid-associated genes are not associated with survival in glioma patients. Journal of Neuro-Oncology, 2018, 136, 33-39.	1.4	4
87	The Relationship Between Stimulation Current and Functional Site Localization During Brain Mapping. Neurosurgery, 2021, 88, 1043-1050.	0.6	4
88	Association of Diffusion and Anatomic Imaging Parameters with Survival for Patients with Newly Diagnosed Glioblastoma Participating in Two Different Clinical Trials. Translational Oncology, 2015, 8, 446-455.	1.7	3
89	Phase I cancer clinical trialsâ€. Neuro-Oncology Practice, 2017, 4, 67-72.	1.0	3
90	Relationship between 7T MR-angiography features of vascular injury and cognitive decline in young brain tumor patients treated with radiation therapy. Journal of Neuro-Oncology, 2021, 153, 143-152.	1.4	3

#	Article	IF	CITATIONS
91	Prognostic risk stratification of gliomas using deep learning in digital pathology images. Neuro-Oncology Advances, 2022, 4, .	0.4	3
92	New initiative for Neuro-Oncology Practice: statistics for the practicing clinician. Neuro-Oncology Practice, 2015, 2, 161-161.	1.0	2
93	Correlation of natural language assessment results with health-related quality of life in adult glioma patients. Journal of Neurosurgery, 2021, , 1-7.	0.9	2
94	A core of differentially methylated CpG loci in gMDSCs isolated from neonatal and adult sources. Clinical Epigenetics, 2022, 14, 27.	1.8	2
95	EGFR amplification status for clinical trial inclusion: where do we draw the line?. Neuro-Oncology, 2019, 21, 1215-1216.	0.6	1
96	External controls to improve on glioblastoma clinical trials. Neuro-Oncology, 2022, 24, 257-258.	0.6	1
97	Regression trees and ensembles for cumulative incidence functions. International Journal of Biostatistics, 2022, 18, 397-419.	0.4	1
98	Novel Aggregate Deletion/Substitution/Addition Learning Algorithms for Recursive Partitioning. Journal of Computational and Graphical Statistics, 2018, 27, 146-156.	0.9	0
99	Identification of a foetal epigenetic compartment in adult human kidney. Epigenetics, 2021, , 1-21.	1.3	0
100	TAMI-07. THE IMMUNE MICROENVIRONMENT IN LOWER GRADE GLIOMAS. Neuro-Oncology, 2020, 22, ii214-ii214.	0.6	0
101	Categorizing continuous higmarkers: More consthan pros Neuro-Oncology Practice 2022 9 81-82	1.0	0